Relay Therapeutics Inc
RLAY
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.11B
Close$
$-1.45
107.7% downside
Current Fair Value
107.7% downsideOvervalued by 107.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.11 Billion |
|---|---|
| Enterprise Value | $4.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.61 |
| Beta | 1.7 |
| Outstanding Shares | 202,849,466 |
Return
| Return on Equity | -32.14% |
|---|---|
| Return on Assets | -29.57% |
| Return on Invested Capital | -32.52% |
Valuation & Multiples
| P/E Ratio | -11.96 |
|---|---|
| PEG | -63.11 |
| Price to Sales | - |
| Price to Book Ratio | 4.69 |
| Enterprise Value to Revenue | 388.71 |
| Enterprise Value to EBIT | -13.5 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$960,000
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
$1.62 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.5013▲ 343.35% |
|---|---|
| Total Calls | 668,300▼ 39.39% |
| Total Puts | 2,339,900▲ 3032.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 139.69%▲ 37.58% |
|---|---|
| Total Invested | $4.78B▲ 161.47% |
| Investors Holding | 267▲ 20.00% |
ESG Score
No data
About Relay Therapeutics Inc
2,020 employeesRelay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.